Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis.
Das S, Finney AC, Anand SK, Rohilla S, Liu Y, Pandey N, Ghrayeb A, Kumar D, Nunez K, Liu Z, Arias F, Zhao Y, Pearson-Gallion BH, McKinney MP, Richard KSE, Gomez-Vidal JA, Abdullah CS, Cockerham ED, Eniafe J, Yurochko AD, Magdy T, Pattillo CB, Kevil CG, Razani B, Bhuiyan MS, Seeley EH, Galliano GE, Wei B, Tan L, Mahmud I, Surakka I, Garcia-Barrio MT, Lorenzi PL, Gottlieb E, Salido E, Zhang J, Orr AW, Liu W, Diaz-Gavilan M, Chen YE, Dhanesha N, Thevenot PT, Cohen AJ, Yurdagul A Jr, Rom O.
Das S, et al. Among authors: bhuiyan ms.
Nat Metab. 2024 Sep 27. doi: 10.1038/s42255-024-01134-4. Online ahead of print.
Nat Metab. 2024.
PMID: 39333384